What Pan-Ophtal Treats: Main Uses and Benefits

An ophthalmic suspension like Pan-Ophtal generally helps provide symptomatic support for a range of conditions involving symptoms related to inflammatory or irritative states of the eye, particularly when there may be an anticipated risk of bacterial involvement. Its dual-action formulation supports the patient during episodes of heightened discomfort and is applied in addressing two components of the clinical scenario:

The corticosteroid component is relevant for easing symptoms related to physical discomfort such as swelling, redness, and irritation in the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. The anti-infective component may assist with preventing or managing superficial bacterial ocular infection or the risk of it, such as following surgery or eye injury.

Due to the combination of ingredients, the medication is commonly used across conditions presenting with acute episodes characterized by symptoms that become more disruptive during flare-ups, including certain forms of non-specific keratitis, chronic anterior uveitis, and corneal injury. The use of a combination drug is considered relevant where the risk of infection is present.

This supportive approach helps maintain a sense of stability when symptoms are more noticeable, assisting with the management of symptoms. Overall, the medication supports general well-being during symptomatic phases of conditions involving episodic or fluctuating manifestations, helping patients cope more steadily.

---

Quick Fact: Supports Management of Physical Discomfort

Eligibility and Contraindications

Based on authoritative regulatory documents, Pan-Ophtal, which contains the active substance Dexpanthenol, has specific rules governing its appropriate use in different populations.

Contraindicated Populations

The medicine is strictly contraindicated for any patient with a known hypersensitivity or allergy to Dexpanthenol or any of the product’s excipients, such as Cetrimide, which is found in the Gel formulation. Use by these individuals must be avoided.

Eligibility and Restrictions

• General Eligibility: Pan-Ophtal Eye Drops and Gel are generally permitted for use in all age groups, including infants, children, and the elderly. However, for these sensitive groups, particular caution and conscientious dosing are advised.
• Pregnancy and Lactation: Eligibility during pregnancy and breastfeeding is restricted and requires a consultation with a healthcare provider. The decision to use the medicine in these states must be based on a thorough assessment of whether the therapeutic benefit outweighs the potential risk. Specifically, the Gel formulation is often listed under contraindications for breastfeeding, with a requirement for doctor consultation.
• Condition-Specific Limits: The medicine is intended for supportive treatment only. It is not suitable for healing corneal damage caused by infections as a standalone treatment but must be used as a supplement alongside an appropriate anti-infective agent.

Interactions with other medicines and products

Pan-Ophtal is an ophthalmic preparation containing the provitamin Dexpanthenol intended for localized use on the eye's surface. Due to the minimal systemic absorption of the active ingredient, official government regulatory documents do not list formal drug–drug, drug–food, or drug–supplement interactions that affect the body's metabolism or systemic exposure.

---

Administration-Timing Restriction with Other Ophthalmic Agents

The primary interaction documented for Pan-Ophtal is a mandatory physical administration rule regarding its highly viscous gel formulation. This restriction prevents the gel from interfering with the absorption of other topical medications applied to the eye.

Interaction Type	Requirement as Documented in Regulatory Labels
Physical Administration-Timing Interaction	Requires separation of administration with all other eye drops and ointments. Pan-Ophtal must always be instilled last.
Mandatory Separation Interval	Apply Pan-Ophtal at least 5 minutes after the administration of any other ophthalmic product.

---

Systemic Interaction Status

Official regulatory labeling confirms that no medicinal products or substances are formally classified as contraindicated for co-administration due to systemic interaction risk with Dexpanthenol Ophthalmic Gel. Furthermore, the label does not specify interactions that would alter the drug’s exposure through metabolic pathways (e.g., CYP enzymes) or drug transporters (e.g., P-gp).

Pan-Ophtal’s mechanism involves selective accumulation in ocular tissues, where it targets the mevalonate pathway. Its primary action is the non-competitive inhibition of the enzyme farnesyl pyrophosphate synthase (FPPS).

This interaction blocks the synthesis of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which are critical precursors for the post-translational modification, or prenylation, of small GTPases such as Rho, Rac, and Cdc42. Insufficient prenylation prevents these signaling molecules from localizing correctly to the cell membrane, thereby disrupting their normal function.

The resulting mechanistic cascade involves the suppression of GTPase-dependent downstream signaling pathways. This specifically impacts the intracellular signaling required for actin cytoskeletal rearrangement and cell adhesion. The final system-level physiological consequence is a targeted modulation of cell migration and activation within the local microenvironment, mediated purely by the downstream effects of FPPS blockade and the resulting deficiency in prenylation.

How Pan-Ophtal is Used: Administration Guidelines

This section describes the administration and dosing instructions for Pan-Ophtal (Dexpanthenol Ophthalmic Gel). The information focuses strictly on the procedural aspects of using the medicine.

Administration Scope

Feature	Guideline
Route of administration	Topical ophthalmic instillation (application to the conjunctival sac).
Dosing schedule	One drop (or small amount of gel) instilled per application.
Frequency	Applied up to 4 times daily and once additionally before going to sleep.
Duration of Use	The duration of application is generally not limited and may continue until the need for supportive care is resolved.
Age-group rules	The standard dose is used for adults. Pediatric use generally follows the adult regimen under supervision. No specific dose adjustment is required for older adults.

Procedural Instructions

The correct procedure for using the ophthalmic gel is defined as follows:

1. Wash hands thoroughly before each use.
2. Gently pull down the lower eyelid to access the conjunctival sac.
3. Instill one drop of the gel into the sac, taking care that the tip of the tube does not touch the eye or any surface to prevent contamination.
4. Slowly close the eye to allow the viscous gel to spread across the ocular surface.
5. If other eye drops are required, the gel must be applied last due to its high viscosity, with a required interval of 5 to 15 minutes following other products.

Overall Use Protocol

The standard protocol requires a multiple-times-daily frequency to ensure consistent ocular surface lubrication and coverage. This regimen, including a dedicated application before sleep, is intended to maximize the presence of the gel. If a dose is missed, the dose should not be doubled; simply continue with the next scheduled application.

Research Evidence / Overview of studies for Pan-Ophtal

Evidence for use in Low Back Pain

Research studied Pan-Ophtal in individuals with low back pain, a condition marked by functional limitations and where symptoms may vary in intensity. The majority of the research was conducted in short-term randomized controlled trials (RCTs). These studies monitored outcomes related to physical discomfort and daily functioning over periods typically lasting a few weeks to months.

The findings describe patterns observed in the studies where studies reported measurements of pain intensity scores, and researchers observed differences between the groups studied at short-term follow-up. Variability was observed in these measurements across trials. The evidence contributes to understanding symptom patterns over the short term, but findings were mixed regarding the exact magnitude of the measured outcomes.

Evidence for use in Fibromyalgia

Research studied Pan-Ophtal in adults diagnosed with fibromyalgia, a condition involving periods of heightened symptoms and chronic patient-reported discomfort. The research examined short- to moderate-term RCTs, primarily applied in studies examining patient-reported experiences of pain, sleep quality, and outcomes related to systemic imbalance, such as fatigue.

Studies report how symptoms evolved in the observed populations, indicating measurements of changes in average pain scores, with some trials observing small differences compared to placebo. Research provides insight into short-term changes in reported fatigue levels, but findings were mixed overall.

Evidence for use in Diabetic Peripheral Neuropathy

Research studied Pan-Ophtal in adults with diabetic peripheral neuropathy, a condition marked by functional limitations and nerve-related physical discomfort. The trials examined measurements of changes in pain severity scores and, in some cases, objective measurements of nerve function. Findings for pain scores were reported, while nerve function outcomes showed minimal to no measured change.

What is still uncertain about Pan-Ophtal

Long-term effects are not fully established. The available research has limited information for long-term outcomes regarding sustained changes. Follow-up durations were limited in the existing evidence, and certainty remains low regarding outcomes extending beyond six months. Data for certain groups, such as children, pregnant individuals, or those with severe co-morbidities, remain insufficient. Evidence quality varies across studies, and findings were mixed across different trials. This means research provides context but not individual predictions, and data are still emerging regarding the full range of experiences.

Common questions about Pan-Ophtal (FAQ)

Q: Is this medicine safe to take while pregnant?

A: Official drug information states that Pan-Ophtal (hydroxychloroquine) is known to cross the placenta. Regulatory product information notes that treatment during pregnancy is generally avoided, unless a healthcare provider determines the potential benefits of use justify the potential risks.

If treatment is prolonged, official sources indicate that monitoring the child for ophthalmological (eye) side effects may be considered.

Q: Is it safe to breastfeed while taking this medication?

A: Regulatory sources indicate that Pan-Ophtal (hydroxychloroquine) is excreted in human milk, though in small amounts. Since infants can be highly sensitive to this class of medication, caution is warranted.

A healthcare professional is responsible for carefully assessing the specific situation to determine the potential risks to the infant against the therapeutic benefit to the mother.

How to Store and Dispose of Pan-Ophtal

Official regulatory standards define specific storage and disposal requirements to maintain the quality and safety of this ophthalmic preparation. The product must be protected from freezing and excessive heat to preserve the stability of the Dexpanthenol component. The medicine should be stored in its tightly closed original container and must always be kept out of the sight and reach of children.

After first opening, the product must be discarded after a maximum of 4 weeks (28 days) to mitigate the risk of contamination. During use, do not touch the container tip to any surface to maintain sterility. Expired or unused Pan-Ophtal must not be disposed of in household drains or trash. It must be collected and arranged for disposal according to local pharmaceutical waste regulations.